Acc.22: medtronic renal denervation system demonstrates significant blood pressure reduction through three years

Medtronic adds to its robust clinical program with long-term data demonstrating the continued blood pressure lowering effect of the symplicity renal denervation procedure medtronic also completes enrollment in the spyral htn-on med trial dublin and washington , april 4, 2022 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today announced long-term data from the first 80 patients in the spyral htn-on med trial, which were presented today at the american college of cardiology's 71st annual scientific session (acc.22) late-breaking featured clinical research sessions. the data were also simultaneously published in the lancet .1 in the first 80 patients of the spyral htn-on med trial, the data demonstrated that patients who were prescribed anti-hypertensive medications and treated with the medtronic symplicity spyral™ renal denervation (rdn) system continued to show durable, clinically significant blood pressure reductions through three years.
MDT Ratings Summary
MDT Quant Ranking